neuroplasticity – Page 2

Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review

mycolabadmin

This research review examines how psilocybin, a compound from certain mushrooms, may help treat depression by creating changes in both brain function and psychological experience. Within supportive therapeutic settings, psilocybin appears to increase cognitive flexibility, help people better process emotions, and restore a sense of connection to themselves, others, and the world. The antidepressant benefits seem to work through a combination of direct brain changes and psychotherapeutic factors, rather than through pure pharmacological action alone.

Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine

mycolabadmin

This review examines how psychedelic drugs like ketamine, MDMA, and psilocybin could offer new hope for people with PTSD by working on the brain differently than current medications. These compounds work quickly and help the brain form new neural connections that can help people process traumatic memories more effectively. When combined with therapy, these drugs show promise in reducing PTSD symptoms faster and more effectively than traditional antidepressants. The review also explains how doctors could use personalized medicine approaches using brain scans and genetic testing to determine which treatment would work best for each individual patient.

Behavioral Phenotyping and Metabolomic Comparison of Chemically Synthesized Psilocybin and Psychedelic Mushroom Extract in a Zebrafish Depression Model

mycolabadmin

Researchers compared chemically made psilocybin with whole mushroom extract in zebrafish to test for depression-like effects. Both treatments reversed depressive behaviors and produced similar changes in brain chemicals, though the mushroom extract showed more neurotransmitter precursors. This study demonstrates that zebrafish can be useful models for studying how psychedelics might help treat depression.

The collective lie in ketamine therapy: a call to realign clinical practice with neurobiology

mycolabadmin

This article argues that ketamine therapy is commonly misunderstood as a consciousness-expanding psychedelic when it actually works through a completely different biological mechanism. The real therapeutic benefit comes from the brain’s natural reorganization in the days after treatment, not from the altered states people experience during the session itself. The authors call for medical practitioners to stop emphasizing the dissociative experience and instead focus on helping patients build healthy thought patterns during the recovery period when the brain is most ready to form new connections.

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

mycolabadmin

Scientists have renewed their investigation into psilocybin, a compound found in certain mushrooms, as a potential treatment for depression. Studies show promising results with patients experiencing significant improvements in depressive symptoms, sometimes sustained for months after a single treatment session. When administered in controlled therapeutic environments with professional support, psilocybin appears relatively safe, though it can cause temporary side effects like headaches and anxiety. This research represents an important shift in how we might treat severe depression, especially in patients who haven’t responded to conventional antidepressants.

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity

mycolabadmin

This review examines how psilocybin, the active compound in certain mushrooms, may help treat depression and anxiety by reducing brain inflammation and promoting healthy neurotransmitter function. Both full doses under medical supervision and smaller ‘microdoses’ show promise for mental health conditions. The research suggests psilocybin works by calming the immune system’s inflammatory response while simultaneously supporting the brain’s natural healing and adaptation processes, offering a potential alternative treatment when standard medications don’t work.

Psychedelics and the Serotonin Hypothesis of Eating Disorders

mycolabadmin

This review explores how psychedelic drugs like psilocybin (found in certain mushrooms) might help treat eating disorders by promoting flexible thinking and breaking rigid eating patterns. The authors summarize evidence from animal studies and early clinical trials showing that psychedelics work differently than traditional antidepressants by triggering brain changes that help people adopt new, healthier behaviors. While results are promising, more research is needed to determine the best doses, patient populations, and long-term safety.

Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review

mycolabadmin

This review examines how ketamine and psychedelics affect connections between brain cells. Under stressful conditions, ketamine and psychedelics appear to strengthen these connections in brain areas important for mood and learning. However, the effects are mixed under normal conditions and vary based on dose, sex, and which specific markers are measured. The findings suggest these substances may help restore brain function damaged by stress or substance use.

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia

mycolabadmin

Schizophrenia involves excessive loss of connections between brain cells in areas responsible for emotion and thinking, leading to negative symptoms and cognitive problems. Research shows that small doses of psychedelics like psilocybin can promote the growth of new brain connections and reduce inflammation. The authors suggest that microdosing psychedelics alongside standard treatments might help restore these lost connections and improve symptoms that don’t respond well to current medications.

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework

mycolabadmin

Psychedelic drugs like LSD and psilocybin show promise in treating depression with effects lasting months after single doses. However, scientists debate whether the hallucinations and mystical experiences these drugs produce are necessary for their healing effects. This review proposes a framework to test whether lower doses without hallucinations might still provide antidepressant benefits, similar to how anesthesia-administered ketamine works without the patient’s awareness.

Research Topic: neuroplasticity